NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

227.8B

Vuru Grade

66.34/100

Current Price

$93.90
-0.90 (-0.95%)

Growth Price

$67.73
Overvalued by 27.87%

Stability Price

$24.64
Overvalued by 73.76%

Company Metrics

  • 24.07 P/E
  • 3.88 P/S
  • 3.27 P/B
  • 3.938 EPS
  • 13.46% Cash ROIC
  • 0.35 Cash Ratio
  • 2.719 / 2.87% Dividend
  • 1.11M Avg. Vol.
  • 2.43B Shares
  • 227.8B Market Cap.

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Battle Between Roche's Avastin And Novartis' Lucentis Heats Up
Bidness ETC - Sep 15, 2014
The study say that this renders the practice by health regulatory bodies of favoring Novartis AG (ADR)'s (NVS) costlier drug Lucentis as pointless and unnecessary.
Novartis Wins The Battle Over Bronchodilators Against GSK
Bidness ETC - Sep 8, 2014
Novartis AG ADR (NVS) reported yesterday that its once-daily Ultibro (Breezhaler) bronchodilator outperformed GlaxoSmithKline plc's (ADR) (GSK) twice-daily blockbuster Seretide (Accuhaler) bronchodilator in Phase-III trials.
Pharma Boom: 14 Biosimilars To Debut In The US
Bidness ETC - Sep 13, 2014
Novartis AG (ADR) (NVS) was the first company to file for an. The company wants to sell a biosimilar to Amgen, Inc.'s (AMGN) biotech cancer drug Neupogen, which brought in sales of $1.4 billion last year.
Novartis Stock Reaches 3-Year High On Successful Heart Failure Drug Trials
Bidness ETC - Sep 2, 2014
Novartis AG ADR (NVS) stock rose 4.3% and closed at 85.9 Swiss francs yesterday on the Zurich Exchange. This was the stock's biggest gain since September 2011, driven by successful Phase III trials conducted on Novartis' experimental heart failure drug ...
Pharma Stocks To Watch This Week
Bidness ETC - Sep 8, 2014
Novartis AG (ADR) (NVS) has already presented in the conference, taking GSK head-on with positive Phase III results for its Ultibro Breezhaler.
Pfizer Signs Agreement To Market Novartis' Respiratory Inhalers In UK
Bidness ETC - Sep 4, 2014
Pfizer Inc. (PFE) has entered into an agreement with Novartis AG (ADR) (NVS), under which Pfizer's UK-based business, officially named Pfizer Limited, will be responsible for the commercialization of Novartis' two respiratory inhalers, Seebri ...
Novartis, Global Alliance Collaborate To Search For TB Cure
Bidness Etc - Aug 20, 2014
Switzerland-based Novartis AG (ADR) (NVS) signed a deal today to license its experimental drugs for the treatment of tuberculosis (TB) to the Global Alliance for TB Drug Development (TB Alliance).
Watch List Highlights - Apple Inc. (NASDAQ:AAPL), Novartis AG (ADR) (NYSE ...
Equities Focus (registration) - Sep 12, 2014
Novartis AG (ADR) (NYSE:NVS) Basel disclosed Friday analyses that confirm the high efficacy of the NVS drug Gilenya (fingolimod) in achieving 'no evidence of disease activity' in patients with relapsing-remitting multiple sclerosis.
Novartis's Generics Unit May Benefit From Biomedicine Patent Expiry
Bidness ETC - Aug 26, 2014
Switzerland-based Novartis AG's (NVS) generic unit goes by the name of Sandoz, and it is the number one player in biosimilars.
Amgen Presents Positive Trial Results For Heart Drug Ivabradine
Bidness ETC - Sep 15, 2014
Amgen, Inc. (AMGN) presented positive Phase III trial results yesterday, for its heart failure drug ivabradine at the Heart Failure Society of America's (HFSA) 18th Annual Scientific Meeting being held in Las Vegas.